Intelligence / Healthtech / New Clinical Trials / Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.
Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.
16 Nov 2026: Trial registered · Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 16 Nov 2026
- Title
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)
- Conditions
- Lipid Metabolism Disorders, Healthy Volunteers - Male and Female, Hyperlipoproteinemia(a)
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07937254
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.